$MNOV
MEDICINOVA INC

2013 Q4 Form 10-Q Financial Statement

#000119312513433171 Filed on November 07, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $6.000M $0.00 $84.00K
YoY Change 17547.06% -100.0%
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $1.630M $1.460M $1.570M
YoY Change -2.98% -7.01% -29.6%
% of Gross Profit
Research & Development $940.0K $600.0K $872.6K
YoY Change 20.51% -31.24% -48.06%
% of Gross Profit
Depreciation & Amortization $10.00K $20.00K $20.00K
YoY Change -66.67% 0.0% 100.0%
% of Gross Profit
Operating Expenses $2.573M $2.242M $2.446M
YoY Change 4.81% -8.34% -37.39%
Operating Profit -$2.242M -$2.363M
YoY Change -5.09% -39.53%
Interest Expense -$10.00K $10.00K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 -$10.00K
YoY Change -100.0% -100.0%
Pretax Income $3.410M -$2.235M -$2.373M
YoY Change -240.33% -5.82% -39.0%
Income Tax $0.00 $1.806K $5.818K
% Of Pretax Income 0.0%
Net Earnings $3.413M -$2.237M -$2.379M
YoY Change -240.22% -5.97% -38.91%
Net Earnings / Revenue 56.88% -2832.14%
Basic Earnings Per Share $0.15 -$0.10
Diluted Earnings Per Share $0.14 -$0.10 -$143.5K
COMMON SHARES
Basic Shares Outstanding 22.40M shares 22.31M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.700M $10.70M $5.700M
YoY Change 67.5% 87.72% -34.48%
Cash & Equivalents $6.700M $10.66M $5.745M
Short-Term Investments
Other Short-Term Assets $1.700M $400.0K $600.0K
YoY Change 325.0% -33.33% -25.0%
Inventory
Prepaid Expenses
Receivables $6.000M
Other Receivables $0.00
Total Short-Term Assets $14.38M $11.04M $6.300M
YoY Change 225.24% 75.22% -34.38%
LONG-TERM ASSETS
Property, Plant & Equipment $82.41K $80.80K $100.0K
YoY Change 5.02% -19.2%
Goodwill $9.600M $9.600M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $700.0K $700.0K $700.0K
YoY Change 0.0% 0.0% 0.0%
Other Assets
YoY Change
Total Long-Term Assets $15.16M $15.16M $15.20M
YoY Change 0.12% -0.28% 1.33%
TOTAL ASSETS
Total Short-Term Assets $14.38M $11.04M $6.300M
Total Long-Term Assets $15.16M $15.16M $15.20M
Total Assets $29.55M $26.20M $21.50M
YoY Change 50.99% 21.84% -12.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $33.89K $186.9K $300.0K
YoY Change -93.11% -37.7% -72.73%
Accrued Expenses $240.1K $472.4K $800.0K
YoY Change -23.68% -40.95% -66.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $460.4K $1.099M $1.200M
YoY Change -55.63% -8.38% -64.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.700M $1.700M $1.700M
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $1.700M $1.700M $1.700M
YoY Change 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $460.4K $1.099M $1.200M
Total Long-Term Liabilities $1.700M $1.700M $1.700M
Total Liabilities $4.120M $4.750M $4.800M
YoY Change -12.11% -1.05% -11.11%
SHAREHOLDERS EQUITY
Retained Earnings -$301.4M -$303.7M
YoY Change 1.37%
Common Stock $22.50K $22.38K
YoY Change 29.23%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.124M
YoY Change
Treasury Stock Shares 0.000 shares 0.000 shares
Shareholders Equity $25.43M $21.45M $16.70M
YoY Change
Total Liabilities & Shareholders Equity $29.55M $26.20M $21.50M
YoY Change 50.99% 21.84% -12.6%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income $3.413M -$2.237M -$2.379M
YoY Change -240.22% -5.97% -38.91%
Depreciation, Depletion And Amortization $10.00K $20.00K $20.00K
YoY Change -66.67% 0.0% 100.0%
Cash From Operating Activities -$4.030M -$1.900M -$2.410M
YoY Change 84.86% -21.16% -19.13%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K -$30.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $20.00K -$20.00K $0.00
YoY Change
Cash From Investing Activities -$20.00K $20.00K -$30.00K
YoY Change -166.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K 530.0K 920.0K
YoY Change -84.78% -42.39% -560.0%
NET CHANGE
Cash From Operating Activities -4.030M -1.900M -2.410M
Cash From Investing Activities -20.00K 20.00K -30.00K
Cash From Financing Activities 70.00K 530.0K 920.0K
Net Change In Cash -3.980M -1.350M -1.520M
YoY Change 131.4% -11.18% -52.2%
FREE CASH FLOW
Cash From Operating Activities -$4.030M -$1.900M -$2.410M
Capital Expenditures -$40.00K -$30.00K
Free Cash Flow -$3.990M -$2.380M
YoY Change 83.03% -20.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Deferred Revenue
DeferredRevenue
2500000
CY2012Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
130000 shares
CY2012Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.88
CY2012Q3 mnov Class Of Warrant Or Right Fair Value
ClassOfWarrantOrRightFairValue
100000
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22397943 shares
CY2011Q1 mnov Consists Of Each Firm Commitment Underwritten Public Offering Unit
ConsistsOfEachFirmCommitmentUnderwrittenPublicOfferingUnit
Each unit consisting of one share of common stock and a warrant to purchase one share of common stock
CY2011Q1 mnov Number Of Units In Firm Commitment Underwritten Public Offering
NumberOfUnitsInFirmCommitmentUnderwrittenPublicOffering
2750000 shares
CY2012Q1 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.30 pure
CY2012Q3 mnov Other Asset Amortization Period
OtherAssetAmortizationPeriod
P1Y
CY2012Q3 mnov Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P5Y
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5744523
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22377943 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
220000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2103865 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.55
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2904137 shares
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
220000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.22
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
0 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22377943 shares
CY2013Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
440086
CY2013Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1694163
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1099404
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-77838
CY2013Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
171031
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
326300292
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
186892
CY2013Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
183198
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
21447053
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-303675590
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
2200
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
472426
CY2013Q3 us-gaap Liabilities
Liabilities
4749567
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
22378
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26196620
CY2013Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1956000
CY2013Q3 us-gaap Goodwill
Goodwill
9600241
CY2013Q3 us-gaap Treasury Stock Value
TreasuryStockValue
1124389
CY2013Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
676481
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80801
CY2013Q3 us-gaap Assets
Assets
26196620
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10660849
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
116000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
132000
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1300000
CY2013Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
378248
CY2013Q3 us-gaap Assets Current
AssetsCurrent
11039097
CY2013Q3 mnov Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
118197
CY2013Q3 mnov Maturity Period Of Investment In Cash Equivalents Securities
MaturityPeriodOfInvestmentInCashEquivalentsSecurities
Three months or less
CY2013Q3 mnov In Process Research And Development
InProcessResearchAndDevelopment
4800000
CY2007Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
0.15 pure
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15093124
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17407311 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
220000 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.92
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3328981 shares
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
220000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
4186 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17403125 shares
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1694257
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1037792
dei Entity Registrant Name
EntityRegistrantName
MEDICINOVA INC
dei Amendment Flag
AmendmentFlag
false
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-67957
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
228124
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
94504
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
312293225
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
491853
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
68102
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
14879992
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-296233797
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3163
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
2200
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
314652
CY2012Q4 us-gaap Liabilities
Liabilities
4688049
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
17407
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19568041
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1956000
CY2012Q4 us-gaap Goodwill
Goodwill
9600241
CY2012Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1131086
CY2012Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
667204
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
78474
CY2012Q4 us-gaap Assets
Assets
19568041
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4010530
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
411592
CY2012Q4 us-gaap Assets Current
AssetsCurrent
4422122
CY2012Q4 mnov Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
152046
CY2012Q4 mnov In Process Research And Development
InProcessResearchAndDevelopment
4800000
dei Trading Symbol
TradingSymbol
MNOV
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001226616
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
30251 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
234327 shares
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Revenue Recognition and Deferred Revenue</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">In October 2011, we entered into an agreement with Kissei Pharmaceutical Co., Ltd., or Kissei, to perform research and development services relating to MN-221 in exchange for a non-refundable upfront payment of $2.5&#xA0;million. We assessed the deliverables in accordance with the authoritative guidance and concluded the existence of one deliverable, which was research and development services. Under the terms of the agreement, we are responsible for all costs to be incurred in the performance of these services. Certain of these research and development services were completed in 2012 and the remaining services are expected to be completed after 2014. We are recognizing the $2.5 million payment as revenue as the research and development services are performed. The amount received from Kissei, net of the amount recorded as revenue to date, is included on the balance sheet as deferred revenue and will be recognized as revenue as we perform the remaining services. For the three months ended September&#xA0;30, 2013 and 2012, revenue recorded was $0 and $0.1 million, respectively. For the nine months ended September&#xA0;30, 2013 and 2012, revenue recorded was approximately $3 thousand and $0.8 million, respectively.</font></p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20114289 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6624818
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
79462 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentrations and Credit Risk</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">We maintain cash balances at various financial institutions and such balances commonly exceed the $250,000 insured amount by the Federal Deposit Insurance Corporation. We also maintain money market funds at various financial institutions which are not federally insured, although they are invested primarily in U.S.&#xA0;government securities. We have not experienced any losses in such accounts and management believes that we do not have significant credit risk with respect to such cash and cash equivalents.</font></p> </div>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.99
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8980204 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.</font></p> </div>
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.44
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
867500 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M9D
us-gaap Deferred Revenue Period Increase Decrease
DeferredRevenuePeriodIncreaseDecrease
-3257
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1212882 shares
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
30635
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7451674
us-gaap Operating Income Loss
OperatingIncomeLoss
-7447838
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
4800
us-gaap Net Income Loss
NetIncomeLoss
-7441793
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
5920
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
211962
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
90966
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24514
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2427650
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13292954
mnov Proceeds Or Payments For Issuance Or Repurchase Of Common Stock Net
ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet
6697
mnov Warrants Exercised
WarrantsExercised
121666 shares
mnov Increase Decrease In Accounts Payable Accrued Expenses Income Taxes Payable And Deferred Rent
IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent
-166345
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5023445
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13299651
us-gaap Share Based Compensation
ShareBasedCompensation
719084
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6650319
us-gaap Operating Expenses
OperatingExpenses
7451095
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2350
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
64000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
4800
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
194000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29314
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
3000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
14315
us-gaap Income Taxes Paid
IncomeTaxesPaid
6354
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7441793
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7439443
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9881
us-gaap Revenues
Revenues
3257
mnov Proceeds From Issuance Of Private Placement Net
ProceedsFromIssuanceOfPrivatePlacementNet
3400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
35414 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
249578 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16273247 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9677808
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
60000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8657667 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
750000 shares
us-gaap Deferred Revenue Period Increase Decrease
DeferredRevenuePeriodIncreaseDecrease
-768584
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
83176
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16585172 shares
CY2012Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4234956
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1033764
mnov Proceeds Or Payments For Issuance Or Repurchase Of Common Stock Net
ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet
58619
mnov Warrants Exercised
WarrantsExercised
0 shares
mnov Increase Decrease In Accounts Payable Accrued Expenses Income Taxes Payable And Deferred Rent
IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent
-664938
CY2012Q1 us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
0.70 pure
CY2012Q1 us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
680000
CY2012Q3 mnov Class Of Warrant Or Rights Exercisable Period From Date Of Issuance
ClassOfWarrantOrRightsExercisablePeriodFromDateOfIssuance
P15M
CY2007 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.85 pure
CY2007 mnov Employee Stock Purchase Plan Share Purchase Offering Period
EmployeeStockPurchasePlanSharePurchaseOfferingPeriod
P6M
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
2882258 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-216337289
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
800000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
22027
us-gaap Income Taxes Paid
IncomeTaxesPaid
10952
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8527341
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
680000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-8521523
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2019
us-gaap Revenues
Revenues
768584
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-103108
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8529360
us-gaap Operating Income Loss
OperatingIncomeLoss
-8524174
us-gaap Net Income Loss
NetIncomeLoss
-8527341
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
19376
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-395957
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5057802
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1092383
us-gaap Share Based Compensation
ShareBasedCompensation
540385
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9348601
us-gaap Operating Expenses
OperatingExpenses
9292758
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5818
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
138000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
35519
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-763176
us-gaap Deferred Revenue Period Increase Decrease
DeferredRevenuePeriodIncreaseDecrease
-805837
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
17605485
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2390282
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1735212
us-gaap Repayments Of Debt
RepaymentsOfDebt
15000000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
19159498
us-gaap Income Taxes Paid
IncomeTaxesPaid
75956
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-303675590
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2829785
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
680000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
377205766
us-gaap Interest Paid
InterestPaid
2487343
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-272234157
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-77838
us-gaap Revenues
Revenues
2364064
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
341299
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-303753428
us-gaap Operating Income Loss
OperatingIncomeLoss
-285657475
us-gaap Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
-5982
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-6660
us-gaap Net Income Loss
NetIncomeLoss
-272312468
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
43515677
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
395150
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
343945
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
117280813
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
231924086
us-gaap Share Based Compensation
ShareBasedCompensation
51110015
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10660849
us-gaap Operating Expenses
OperatingExpenses
288021539
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
17605485
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
78311
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2500000
us-gaap Interest Expense
InterestExpense
3605818
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
261645
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
14670000
us-gaap Cost Of Revenue
CostOfRevenue
1258421
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2105918
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
377918240
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4925948
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
169482305
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
85572825
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
145958179
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
98445
mnov Deemed Dividend Resulting From Convertible Preferred Stock
DeemedDividendResultingFromConvertiblePreferredStock
31264677
mnov Restricted Assets Cash Unrestricted Upon Conversion Of Convertible Notes
RestrictedAssetsCashUnrestrictedUponConversionOfConvertibleNotes
1881815
mnov Impairment Charge Gain Net On Investment Securities And Ars Put
ImpairmentChargeGainNetOnInvestmentSecuritiesAndArsPut
-1735212
mnov Proceeds Or Payments For Issuance Or Repurchase Of Common Stock Net
ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet
-1158171
mnov Impairment Of Sublease
ImpairmentOfSublease
35259
mnov Increase Decrease In Accounts Payable Accrued Expenses Income Taxes Payable And Deferred Rent
IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent
378689
mnov Amortization Of Premium Discount On Investment Securities Convertible Notes And Debt Discount And Issuance Costs
AmortizationOfPremiumDiscountOnInvestmentSecuritiesConvertibleNotesAndDebtDiscountAndIssuanceCosts
1099365
mnov Proceeds From Conversion Of Convertible Notes
ProceedsFromConversionOfConvertibleNotes
1881253
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
19864 shares
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
735000 shares
CY2012Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
100000
CY2012Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4090
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2378768
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2372950
CY2012Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2864
CY2012Q3 us-gaap Revenues
Revenues
83787
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2375904
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2362711
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-2378768
CY2012Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
14329
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1573943
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
2446498
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5818
CY2012Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
872555
CY2012Q3 mnov Warrants Exercised
WarrantsExercised
0 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
14184 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22301773 shares
CY2013Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2013Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
0
CY2013Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
7798
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2236750
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2234944
CY2013Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
756
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2235994
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2242347
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-2236750
CY2013Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
395
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1456774
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
2242347
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1806
CY2013Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
785573
CY2013Q3 mnov Warrants Exercised
WarrantsExercised
0 shares

Files In Submission

Name View Source Status
0001193125-13-433171-index-headers.html Edgar Link pending
0001193125-13-433171-index.html Edgar Link pending
0001193125-13-433171.txt Edgar Link pending
0001193125-13-433171-xbrl.zip Edgar Link pending
d595996d10q.htm Edgar Link pending
d595996dex103.htm Edgar Link pending
d595996dex311.htm Edgar Link pending
d595996dex312.htm Edgar Link pending
d595996dex321.htm Edgar Link pending
d595996dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mnov-20130930.xml Edgar Link completed
mnov-20130930.xsd Edgar Link pending
mnov-20130930_cal.xml Edgar Link unprocessable
mnov-20130930_def.xml Edgar Link unprocessable
mnov-20130930_lab.xml Edgar Link unprocessable
mnov-20130930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending